SG11202003280SA - Compositions and methods for the depletion of cd117+ cells - Google Patents

Compositions and methods for the depletion of cd117+ cells

Info

Publication number
SG11202003280SA
SG11202003280SA SG11202003280SA SG11202003280SA SG11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA
Authority
SG
Singapore
Prior art keywords
depletion
compositions
cells
methods
Prior art date
Application number
SG11202003280SA
Other languages
English (en)
Inventor
Bradley R Pearse
Michael Cooke
Anthony Boitano
Rahul Palchaudhuri
Sean Mcdonough
Rajiv Panwar
Jacob Glanville
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of SG11202003280SA publication Critical patent/SG11202003280SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202003280SA 2017-10-24 2018-10-23 Compositions and methods for the depletion of cd117+ cells SG11202003280SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762576572P 2017-10-24 2017-10-24
US201762596569P 2017-12-08 2017-12-08
US201862632967P 2018-02-20 2018-02-20
US201862638053P 2018-03-02 2018-03-02
PCT/US2018/057180 WO2019084064A2 (en) 2017-10-24 2018-10-23 COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Publications (1)

Publication Number Publication Date
SG11202003280SA true SG11202003280SA (en) 2020-05-28

Family

ID=66247007

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003280SA SG11202003280SA (en) 2017-10-24 2018-10-23 Compositions and methods for the depletion of cd117+ cells

Country Status (12)

Country Link
US (2) US10899843B2 (de)
EP (1) EP3700568A4 (de)
JP (2) JP7280254B2 (de)
KR (1) KR20200069364A (de)
AU (1) AU2018355244A1 (de)
BR (1) BR112020008228A2 (de)
CA (1) CA3079897A1 (de)
CO (1) CO2020004906A2 (de)
IL (1) IL274154A (de)
MX (1) MX2020004140A (de)
SG (1) SG11202003280SA (de)
WO (1) WO2019084064A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700540A4 (de) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen
EP3700568A4 (de) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
EP3959242A4 (de) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. Anthracyclin-antikörper-wirkstoff-konjugate und verwendungen davon
EP3958902A4 (de) * 2019-04-24 2023-01-25 Magenta Therapeutics, Inc. Anti-cd117-antikörper und verwendungen davon
CA3134689A1 (en) * 2019-04-24 2020-10-29 Anthony Boitano Conditioning methods for gene therapy
MX2021014729A (es) * 2019-06-04 2022-02-25 Magenta Therapeutics Inc Metodos y composiciones para tratar enfermedades autoinmunitarias.
AU2020286508A1 (en) * 2019-06-05 2022-01-06 Heidelberg Pharma Research Gmbh T-cell depleting therapies
US20230183344A1 (en) * 2020-03-16 2023-06-15 Magenta Therapeutics, Inc. T-cell bispecific binding proteins
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
AU2022409748A1 (en) 2021-12-16 2024-05-23 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd117 for use in cell therapy
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
AU5794998A (en) 1996-12-13 1998-07-03 Human Genome Sciences, Inc. Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes
US6372448B1 (en) 1998-12-30 2002-04-16 Millennium Pharmaceuticals, Inc. Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2007054816A2 (en) 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ES2371085T3 (es) 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
EP3255061B1 (de) 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selektive immundepletion einer endogenen stammzellennische zur transplantation
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
EP2842573B1 (de) 2008-11-07 2017-09-27 Galaxy Biotech, LLC Monoklonale Antikörper gegen den Fibroblasten-Wachstumsfaktor-Rezeptor 2
US9233173B2 (en) 2009-04-08 2016-01-12 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2011102551A1 (en) 2010-02-18 2011-08-25 Meiji Seika Kaisha, Ltd. Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa
RU2584597C2 (ru) 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
EP2436398B1 (de) 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxinkonjugate mit verbesserten Linkern
WO2012103165A2 (en) * 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2497499A1 (de) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxinkonjugate mit verbesserten Verknüpfungen
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
EP2774624A1 (de) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxinderivate
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
EP3019629A4 (de) 2013-07-12 2017-01-18 Biogen International Neuroscience GmbH Genetische und bild-biomarker für den abnahme von kognitiven fähigkeiten und hirnglucosestoffwechsel bei personen mit morbus alzheimer oder mit anfälligkeit für die entstehung von morbus alzheimer
US10421802B2 (en) 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
EP3065773A1 (de) * 2013-11-05 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Humane neutralisierende anti-kit-antikörper und verwendungen davon
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US9938323B2 (en) 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
CN107636016B (zh) * 2015-03-09 2022-02-11 海德堡医药有限责任公司 鹅膏毒素-抗体轭合物
CA2980748A1 (en) 2015-03-25 2016-09-29 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
EP3280720A4 (de) 2015-04-06 2018-12-05 President and Fellows of Harvard College Zusammensetzungen und verfahren zur nicht-myeloablativen konditionierung
CA2981851A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016164745A1 (en) 2015-04-10 2016-10-13 The Methodist Hospital System Cd117 ligand-drug conjugates for targeted cancer therapy
CN108602887B (zh) 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
EP3370768B9 (de) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Spezifisch an pd-1 bindende antikörper und deren verwendung
CN109071658A (zh) 2016-02-05 2018-12-21 根马布股份公司 具有改进的内化特性的多特异性抗原-结合分子
WO2017046658A1 (en) 2016-04-20 2017-03-23 Hangzhou Dac Biotech Co, Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
IL303455A (en) 2016-06-17 2023-08-01 Crispr Therapeutics Ag Compositions and methods for depleting CD117 plus cells
US20200188527A1 (en) 2017-03-31 2020-06-18 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
EP3700568A4 (de) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen
EP3700540A4 (de) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen

Also Published As

Publication number Publication date
BR112020008228A2 (pt) 2020-10-13
CO2020004906A2 (es) 2020-05-05
KR20200069364A (ko) 2020-06-16
CN111372608A (zh) 2020-07-03
WO2019084064A3 (en) 2019-06-20
US11958908B2 (en) 2024-04-16
WO2019084064A4 (en) 2019-08-08
WO2019084064A2 (en) 2019-05-02
IL274154A (en) 2020-06-30
EP3700568A2 (de) 2020-09-02
JP2021500375A (ja) 2021-01-07
AU2018355244A1 (en) 2020-04-09
MX2020004140A (es) 2020-08-13
US10899843B2 (en) 2021-01-26
EP3700568A4 (de) 2021-11-10
JP7280254B2 (ja) 2023-05-23
US20210206872A1 (en) 2021-07-08
JP2023113666A (ja) 2023-08-16
CA3079897A1 (en) 2019-05-02
US20190153114A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
IL263744A (en) Compositions and methods for depleting cd117 plus cells
SG11202003280SA (en) Compositions and methods for the depletion of cd117+ cells
IL263743A (en) Cell depletion compositions and methods
EP3700540A4 (de) Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen
IL268058A (en) Compositions and methods for depleting CD137 plus cells
IL275263A (en) Preparations and methods for inhibiting T cell exhaustion
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
SG11202004116QA (en) T cell manufacturing compositions and methods
IL255932A (en) New antigenic determinant cells and their combination for use in immunotherapy of myeloma and other cancers
HK1256726A1 (zh) 載體結合劑組合物及其製備和使用方法
IL269334A (en) Improved compositions of t cells and methods
IL268684A (en) Preparations and methods for immuno-oncology
GB201807325D0 (en) Compositions and methods
IL255480B (en) Preparations containing mesenchymal stem cells and their uses
SG11202004192XA (en) Compositions and methods for the depletion of cd2+ cells
SG11202004294XA (en) Compositions and methods for the depletion of cd5+ cells
IL274524A (en) Preparations and methods for aquaculture
IL271022A (en) Compositions and methods for providing cell replacement therapy
IL263341A (en) Stem cell material, compounds and methods of use
IL278201A (en) Methods and preparations for depleting cytotoxic T cells
IL264977A (en) Methods and preparations for the treatment of melanoma
GB202014449D0 (en) Compositions and methods of cell attachment
ZA202004533B (en) Skin-brightening compositions and methods
HK1254866A1 (zh) 用於骨髓瘤和其他癌症免疫治療的新型細胞表位和細胞表位組合物
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents